#Newlab #ESI #NewPI @TheWistar #gdTcells

Human #gdTCells that contain the Cγ1 form of the γ chain constant domain are more cytotoxic and expanded in colorectal #tumors when compared with cells that contain Cγ2, which express wound-healing genes. Learn more in Science #Immunology: scim.ag/4qwecQw

IN8bio Announces Pricing of Private Placement of up to $40.2 Million. Financing led by Coastlands Capital with participation from new and existing biotechnology investors. $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application. Read the full press release: bit.ly/4apRHsg $INAB #CancerZero #GDTCells

In anticipation of our upcoming new TCE data release at ACR later this month, our COO, Kate Rochlin, PhD, will present an overview of our novel Gamma-delta T Cell Engager Program at the T-Cell Engager for Autoimmune Disease Summit in Boston on October 16th, 2025.  Our unique TCE functions to both activate and expand gamma-delta T cells, driving deep target cell depletion. This exciting platform brings the power of these cells to autoimmune disease. Kate will deliver an oral presentation and participate in a panel discussion tomorrow. We hope to see you there! Learn More: bit.ly/3W9dzQh. $INAB #GDTCells

We are so excited to announce the achievement of our 4-year progression-free glioblastoma patient!  Thank you, @Nasdaq, for marking this momentous occasion for us at the Tower in Times Square.  The patient had a grade 4, IDH-mutant, MGMT-methylated glioma treated with the INB-200 gamma-delta T cell therapy in the glioblastoma trial. IN8bio recently presented updated Phase 1 data from the INB-200 trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.  The results showed that repeated doses of INB-200 demonstrated an extended mPFS of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care Stupp protocol in newly diagnosed #GBM. INB-200 is the first genetically modified gamma-delta T  cell therapy evaluated in GBM and has demonstrated a favorable safety profile and signals of long-term benefit. Read more: bit.ly/3Hv14KJ #GBMSurvivor #CancerZero #GDTcells #CancerResearch #Glioblastoma $INAB

IN8bio recognizes the achievement of an INB-200-treated patient who has reached 4 years in remission in the glioblastoma trial. This milestone is significant for the patient who presented with a grade 4, IDH-mutant, MGMT- methylated glioma and was treated with IN8bio’s gamma-delta T cell therapy. Read more: bit.ly/3Hv14KJ INB-200 is the first genetically modified gamma-delta T cell therapy evaluated in GBM and has demonstrated favorable safety and potential benefit. Join us in our fight to achieve Cancer Zero! $INAB #GBMSurvivor #CancerZero #GDTcells #CancerResearch #GBM

IN8bio’s DRI technology is designed to treat newly diagnosed GBM by harnessing the natural tumor-targeting power of gamma-delta T cells and the sensitizing effects of chemotherapy. This approach aims to eliminate residual GBM cancer cells that can persist and lead to relapse. Learn more about our DeltEx Platform: in8bio.com/. #CancerZero #GDTcells #CancerResearch #Glioblastoma

IN8bio is pleased to announce updated Phase 1 results of INB-200, IN8bio’s proprietary Drug Resistant Immunotherapy (DRI) gamma-delta T cells in newly diagnosed GBM.  GBM is a devastating disease, and we believe these promising results demonstrate the potential of gamma-delta T cells to change the outcomes for these patients.  You can access the complete press release and find the link to this morning's company webcast playback here: bit.ly/43mjohI.  $INAB #CancerZero #GDTcells #CancerResearch

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival. Join us today, June 2nd at 8:30 am, for a company conference call to discuss the data with IN8bio management and Dr. Burt Nabors, the lead clinical investigator. Read the full press release for the webcast link: bit.ly/43mjohI. $INAB #ASCO2025 @ASCO #ASCO2025 #GDTcells #GammaDeltaTCells

Glioblastoma is a devastating brain cancer with a 5-year survival rate of less than 7%. Despite decades of research, treatment options are limited. We urgently need bold innovation, new therapies, and cutting-edge technologies like immunotherapy. IN8bio’s INB-200 therapy uses genetically modified, chemotherapy-resistant gamma-delta T cells, which can target tumor cells while sparing healthy tissue, offering a novel approach to combat glioblastoma. These patients are in the fight of their lives, and we won’t let them go it alone. Together, we can push the boundaries of what is possible and redefine the future of patient care.  #BrainTumorAwareness  #CancerZero #GBM #BrainCancer #Immunotherapy #BrainCancer #GDTcells $INAB

At IN8bio, we believe innovation can’t wait. The INB-200 trial harnesses the power of our engineered gamma-delta T cell therapy to address one of the biggest challenges in oncology: Glioblastoma, a devastating cancer with a mere 12-month median survival rate. Despite being identified nearly a century ago, only four drugs and one device have ever gained approval for its treatment—a stark reminder of the urgent need for breakthroughs. With new clinical data to be presented at #ASCO2025, we’re pushing forward—because patients and their families deserve, more, they deserve a future redefined by possibility. #Glioblastoma #CancerResearch #GBM #Immunotherapy #CellularTherapy #GDTCells $INAB

Congratulations to @IN8bio's Senior Director of Analytics, Mariska ter Haak, who won the Host Region (U.S. East) Abstract Award at ISCT 2025! This prestigious and competitive recognition showcases how IN8bio’s technology and know-how create consistent, powerful cellular therapies. Mariska delivered an excellent oral presentation and poster on the use of deep analytics to characterize the gene expression and repertoire analysis changes that occur in the clinical manufacturing of IN8bio's gamma-delta T-cell therapies. Read more: bit.ly/4ke5W4S $INAB #Manufacturing #GDTcells

Our CEO and co-founder, William Ho (@Willhonyc), will present today at the 2025 Jones Healthcare and Technology Innovation Conference in Las Vegas, NV. We hope you join us for the webcast at 9:30 AM PDT / 12:30 PM EDT. Register to watch: bit.ly/in8bioevents $INAB #GDTCells IN8bio

Our CEO and co-founder, William Ho (@Willhonyc), will present today at the 2025 Jones Healthcare and Technology Innovation Conference in Las Vegas, NV. We hope you join us for the webcast at 9:30 AM PDT / 12:30 PM EDT. Register to watch: bit.ly/in8bioevents $INAB #GDTCells IN8bio

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025. Read more here: bit.ly/4iLuRwl $INAB #CancerZero #GDTcells @AACR #AACR25

We are happy to announce that our COO, Kate Rochlin, PhD, will present this week at BioProcessing International US West 2025 in San Diego, CA.  Today, she is giving a company presentation on IN8bio's INB-100 clinical program, highlighting the DeltEx Allo gamma-delta T cell manufacturing platform. She will discuss how to think broadly about cell therapy manufacturing scale-up and considerations for phase-appropriate development.   She will also participate in a panel on Thursday, "Preparing for the Future of ATMP Commercialization & Attracting Investment to Avoid Roadblocks." We hope to see you there! $INAB #BPIWest #GDTcells @BioprocessIC

#NEWS: We are pleased to report our fourth-quarter and full-year 2024 financial results and recent business highlights. Read the press release for full details: bit.ly/43MCU7w $INAB #IN8bio #CancerZero #GDTCells

We are hiring!!! If you are interested in #gdTcells or #Staph this is the position for you!! Post-Doctoral Research Fellow in Immunology at Trinity College Dublin, The University of Dublin jobs.ac.uk/job/DLH422/post-d…

Our CEO and co-founder, William Ho, will present at #BiotechShowcase 2025 in San Francisco, CA! He will participate in a panel on Monday, January 13th and deliver a company presentation on Tuesday, January 14th. Read more: bit.ly/3W5NYIe $INAB #JPM25 #GDTCells

We have made remarkable progress with our gamma-delta T cell therapies this year as we advance our #CancerZero mission. We look forward to continuing together in 2025! Happy New Year from all of us at IN8bio! #IN8bio $INAB #GDTCells #Oncology